Herbruck Alder to Convene Summit on the New Healthcare Reform Law

CLEVELAND, Aug. 3 /PRNewswire/ -- Herbruck Alder, a Cleveland-based employee benefits firm, will bring together executives from five medical insurance companies to update employers about the new federal healthcare reform law at a special forum on Thursday, August 12 at La Centre Conference Center in Westlake.

Invited to the conference, which takes place from 8:30 a.m. to 1:30 p.m., are human resources executives, CFOs, Presidents, Owners and other institutional healthcare decision-makers.

"The speakers will offer insight on different aspects of the coming changes, which are critical to organizations and their employees," says Mark Alder president of Herbruck Alder.

Participating with Herbruck Alder will be Aetna, Anthem Blue Cross and Blue Shield, Kaiser Permanente, Medical Mutual of Ohio, and UnitedHealthcare.  A representative from each will moderate a breakout session in the morning.

During lunch, a panel with expertise in employee benefits, law, finances, and human resources will discuss how the new law will impact employers.  On the panel are James M. Drozdowski, partner of the law firm of Hahn Loeser & Park; Debbie Connelly, Vice President of Human Resources, Hyland Software; Peter A. DeMarco, Vice President and Director of Tax Services Group of the accounting firm of Meaden & Moore, and Christopher G. Herbruck, Vice President, Herbruck Alder.

La Centre is on Detroit Road near the I-90 interchange at Columbia Road. For reservations, please contact Alison Muth at 216.623.2600 or go to www.herbruckalder.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Mark  Alder   |   https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=93381

SOURCE Herbruck Alder

Suggested Articles

Blues plans have reportedly agreed to a $2.7 billion antitrust settlement.

Premera Blue Cross will pay $6.9 million to HHS over a data breach six years ago that exposed 10 million people's health information.

HHS and the FDA finalized a rule that enables states to seek approval to re-import certain drugs from Canada for a cheaper price.